Oxford Biomedica (OXB) RNS Announcements

Add to Alert list
Date Time Source Announcement
12 Mar 2001 05:10 PM
RNS
Director Shareholding
12 Mar 2001 07:01 AM
RNS
Corporate Action
12 Mar 2001 07:01 AM
RNS
Full List/Placing& Open Offer
14 Feb 2001 03:59 PM
RNS
Additional Listing
13 Feb 2001 10:48 AM
RNS
Appointment
05 Feb 2001 07:00 AM
RNS
Acquisition of Technology
01 Feb 2001 04:35 PM
RNS
Access to Antibody Technology
26 Jan 2001 07:00 AM
RNS
Preliminary Results 2000
22 Jan 2001 07:00 AM
RNS
Agreement with AHP Signed
02 Jan 2001 05:13 PM
RNS
Board Appointment
02 Jan 2001 07:13 AM
RNS
TroVax into Clinical Trials
13 Dec 2000 07:00 AM
RNS
Collaboration with Valentis
04 Dec 2000 07:00 AM
RNS
New Technology Developed
06 Nov 2000 07:00 AM
RNS
First Clinical Trials
16 Oct 2000 07:00 AM
RNS
Ethical Approval for Trovax
28 Sep 2000 09:53 AM
RNS
Director Shareholding
26 Sep 2000 07:30 AM
RNS
Bioinformatics Collaboration
23 Aug 2000 11:51 AM
RNS
Employee Share Options
17 Aug 2000 04:17 PM
RNS
Additional Listing
16 Aug 2000 07:00 AM
RNS
Interim Results 2000
15 Aug 2000 05:48 PM
RNS
Additional Listing
15 Aug 2000 11:02 AM
RNS
Additional Listing
15 Aug 2000 07:00 AM
RNS
Research Update
10 Aug 2000 07:00 AM
RNS
Re Successful Fund Raising
08 Aug 2000 12:40 PM
RNS
Additional Listing
07 Aug 2000 01:25 PM
RNS
Statement re Press Comment
26 Jun 2000 08:21 AM
RNS
Research Update
06 Jun 2000 07:00 AM
RNS
Agreement
18 May 2000 11:05 AM
RNS
Agreements Signed, etc
02 May 2000 11:14 AM
RNS
Therapeutic Genes for Treatment of Cancer Acquired
31 Mar 2000 01:27 PM
RNS
Directors' Notification of Dealing in Shares
23 Mar 2000 04:29 PM
RNS
Directors' Dealings
21 Mar 2000 11:23 AM
RNS
Paul Durrands Appointed as Commercial Director
20 Mar 2000 12:08 PM
RNS
Agreement Signed with Nycomed Amersham Imaging
16 Mar 2000 08:39 AM
RNS
Human Genome/Patenting
08 Mar 2000 04:58 PM
RNS
Directors' Dealings
28 Feb 2000 08:19 AM
RNS
Gene Therapy Patent Obtained in the USA
24 Feb 2000 07:01 AM
RNS
Final Results - Year Ended 31 December 1999
21 Feb 2000 07:01 AM
RNS
Deal Signed on Novel Tumour Vaccine
14 Feb 2000 07:02 AM
RNS
Collaboration Agreement Signed with AstraZeneca
02 Feb 2000 07:01 AM
RNS
Successful Developments in Macrogen Cancer Therapy
24 Jan 2000 02:58 PM
RNS
Response to Press Comment on FDA Ruling
20 Jan 2000 04:13 PM
RNS
Holding in Company
20 Jan 2000 02:14 PM
RNS
Collaboration Agreement Signed - Replacement
20 Jan 2000 11:08 AM
RNS
Collaboration Agreement Signed with IDM
17 Jan 2000 07:01 AM
RNS
Issue of Shares
07 Jan 2000 07:01 AM
RNS
New Development in Cancer Therapy
21 Dec 1999 02:02 PM
RNS
Acquisition of Novel Antibody Technology Complete
22 Nov 1999 04:11 PM
RNS
Holding in Company
16 Nov 1999 07:14 AM
RNS
Preclinical Results - Parkinson's Disease Product

Oxford Biomedica is a company that specialises in cell and gene therapy, and is a leader in the development of gene-based medicines. They work with pharmaceutical and biotechnology companies to develop and manufacture viral vectors, including lentivirus, adeno-associated virus, and adenoviral vectors.

Headquartered in Oxford, Oxford Biomedica has manufacturing facilities in Oxfordshire, UK, Lyon and Strasbourg, France, and near Boston, MA, US.

Oxford Biomedica share price listed in London under the ticker OXB at 2,570p.

UK 100

Latest directors dealings